These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34095457)

  • 1. In Vivo Editing of Macrophages through Systemic Delivery of CRISPR-Cas9-Ribonucleoprotein-Nanoparticle Nanoassemblies.
    Lee YW; Mout R; Luther DC; Liu Y; Castellanos-García L; Burnside AS; Ray M; Tonga GY; Hardie J; Nagaraj H; Das R; Phillips EL; Tay T; Vachet RW; Rotello VM
    Adv Ther (Weinh); 2019 Oct; 2(10):. PubMed ID: 34095457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
    Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
    Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
    Zhang S; Shen J; Li D; Cheng Y
    Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
    Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
    Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
    Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH
    J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytosolic and Nuclear Delivery of CRISPR/Cas9-ribonucleoprotein for Gene Editing Using Arginine Functionalized Gold Nanoparticles.
    Mout R; Rotello VM
    Bio Protoc; 2017 Oct; 7(20):. PubMed ID: 29226180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical and Functional Characterization of Differential CRISPR-Cas9 Ribonucleoprotein Complexes.
    Camperi J; Moshref M; Dai L; Lee HY
    Anal Chem; 2022 Jan; 94(2):1432-1440. PubMed ID: 34958212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanidinium-Rich Lipopeptide-Based Nanoparticle Enables Efficient Gene Editing in Skeletal Muscles.
    Zhu M; Wang X; Xie R; Wang Y; Xu X; Burger J; Gong S
    ACS Appl Mater Interfaces; 2023 Mar; 15(8):10464-10476. PubMed ID: 36800641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application.
    Sun B; Chen H; Gao X
    J Control Release; 2021 Sep; 337():698-717. PubMed ID: 34364918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing.
    Yao X; Lyu P; Yoo K; Yadav MK; Singh R; Atala A; Lu B
    J Extracell Vesicles; 2021 Mar; 10(5):e12076. PubMed ID: 33747370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing.
    Whitley JA; Cai H
    J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing.
    Chen Y; Ping Y
    Acc Chem Res; 2023 Aug; 56(16):2185-2196. PubMed ID: 37525893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Simple and Efficient CRISPR/Cas9 System Using a Ribonucleoprotein Method for
    Liu J; Cui H; Wang R; Xu Z; Yu H; Song C; Lu H; Li Q; Xing D; Tan Q; Sun W; Zou G; Shang X
    J Fungi (Basel); 2022 Sep; 8(10):. PubMed ID: 36294565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-encapsulation of Cas9 mRNA and guide RNA in polyplex micelles enables genome editing in mouse brain.
    Abbasi S; Uchida S; Toh K; Tockary TA; Dirisala A; Hayashi K; Fukushima S; Kataoka K
    J Control Release; 2021 Apr; 332():260-268. PubMed ID: 33647431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 (
    Shen Y; Cohen JL; Nicoloro SM; Kelly M; Yenilmez B; Henriques F; Tsagkaraki E; Edwards YJK; Hu X; Friedline RH; Kim JK; Czech MP
    J Biol Chem; 2018 Nov; 293(44):17291-17305. PubMed ID: 30190322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
    Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of Cas9/sgRNA Ribonucleoprotein Complexes via Hydroxystearyl Oligoamino Amides.
    Kuhn J; Lin Y; Krhac Levacic A; Al Danaf N; Peng L; Höhn M; Lamb DC; Wagner E; Lächelt U
    Bioconjug Chem; 2020 Mar; 31(3):729-742. PubMed ID: 31967454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
    Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
    J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
    Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C
    Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.